Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lyell Immunopharma Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://www.lyell.com
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Lynn Seely, MD
Number Of Employees: 300
Enterprise Value: $-144,211,800
PE Ratio: -0.35
Exchange/Ticker 1: NASDAQ:LYEL
Exchange/Ticker 2: N/A
Latest Market Cap: $149,828,704
BioCentury | Apr 2, 2025
Management Tracks
Change at the top for Phathom as Basta replaces Curran
Plus: Updates from Nuage, GV, Inhibrx, Lyell, Repare, Adcendo, ITM Isotope, Transgene and Novartis
BioCentury | Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
BioCentury | Nov 21, 2024
Product Development
Companies get creative with multi-targeted CARs at SITC, ASH
BioCentury’s analysis of the SITC, ASH abstracts highlights progress in bicistronic and tandem CAR Ts
BioCentury | Aug 13, 2024
Management Tracks
Lyell, Juno veteran Albertson becomes Caribou’s CMO
Plus: 10x names CCO, CFO and updates from Ovid, Cerevance, Fore, Atavistik, Velia, SpyBiotech, Telomir, Sernova and Holoclara
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Jul 3, 2024
Product Development
Clinical Report: Updates in myasthenia gravis from J&J, Cartesian
Plus: Readouts for Savara, Lyell and Novo Nordisk
BioCentury | Jun 27, 2024
Management Tracks
Foresite promotes Hyung Chun, Cindy Xiong to partner
Plus: Peter Flynn at the helm at Arialys, and updates from Augustine, CND, Parallel Bio and Zevra
BioCentury | Jun 13, 2024
Discovery & Translation
Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 6, 2024
Discovery & Translation
Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more
BioCentury’s roundup of translational innovations
BioCentury | Mar 7, 2024
Discovery & Translation
Science spotlight: Roche’s anti-TIGIT mAb benefits from Fc-driven effects and more
BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 54